Experience

Avadel Pharmaceuticals plc
• Biotechnology Research
• 100 - 200 Employee
• VP of Sales & Commercial Operations

  • Oct 2022 - Present

EVERSANA
• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee
• Chief Commercial Officer

  • Jul 2021 - Oct 2022


ATJ Consulting

• Biotechnology

• President

  • 2019 - Jul 2021

  Builds sustainable commercial strategies for innovative pharmaceutical/biotech clients, focusing on rare disease patient populations. Projects include primary market research, competitive analysis, go-to-market strategy, sales force deployments, and HUB/reimbursement/patient services models. Builds sustainable commercial strategies for innovative pharmaceutical/biotech clients, focusing on rare disease patient populations. Projects include primary market research, competitive analysis, go-to-market strategy, sales force deployments, and HUB/reimbursement/patient services models.



STEM Healthcare

• United States
• Wellness and Fitness Services

• President - North America

  • Jun 2018 - Jul 2019

  Boutique UK-based consultancy driving brand strategy for 40+ companies, including biotech start-ups and 23 of the largest 25 pharmaceutical companies. Reported to the Global CEO who previously established the North American market. Responsible for developing the strategic transformation from proof of concept to a rapidly growing, sustainable business. As a member of the STEM Board, held responsibility for global strategy and organizational leadership. • Delivered 25% year-over-year revenue growth in FY19 with a team of 25 while transforming the business model to drive profitability and define back-office investments required to scale operations. • Repositioned core marketing message to focus on all elements from brand strategy to execution, mitigating the business's growing perception solely as a sales force effectiveness tool. • Developed vision and provided leadership to a young team by investing in their professional growth and development.



Mallinckrodt Pharmaceuticals

• Ireland
• Pharmaceutical Manufacturing
• 700 & Above Employee

• VP/GM Sales & Marketing, Neurological Rare Diseases

  • May 2015 - Oct 2017

  Promoted to assume $350M P&L responsibility for H.P. Acthar Gel’® indications in Infantile Spasms and Multiple Sclerosis relapses, part of Mallinckrodt's largest business, a $1.2B drug focused on treating autoimmune and rare diseases. Led 100+ sales and marketing professionals through transformational change to selectively target growth areas while maximizing profitability in a mature phase of the product lifecycle.• Integrated $5.3B acquisition and increased market share from 45% to 52% for ultra-orphan Infantile Spasms indication.• Built out an entirely new marketing team and stood up commercial headquarters in Bedminster, NJ. • Revamped marketing strategy for H.P. Acthar Gel® to drive depth and breadth of prescribing, focused on the selling message, reimbursement model, and scientific rationale for the appropriate patients. • Led strategic Phase IV studies by partnering with cross-functional teams to advance on-market and pipeline assets.

• Global Lead and VP/GM Sales & Marketing, Intrathecal Therapies

  • Feb 2014 - May 2017

  Held full P&L responsibility for $50M 505(b)(2), buy & bill business focused on treating severe spasticity across multiple neurological disease states utilizing drug/device combination therapy for delivery of Gablofen® (baclofen) across the United States and seven markets in Europe.• Doubled Gablofen's growth trajectory from 13% to 26% in Year 1 by revamping commercial strategy to focus on intrathecal education 'Beyond the Refill,' creating a long-term, sustainable growth plan.• Over 3.5 years, doubled revenue organically from $22M to $45M and achieved 60% market share.• Initiated first-ever cross-functional strategic brand planning process, which was then scaled organization-wide.• Integrated commercial, medical, regulatory, and R&D upon $100M acquisition of CNS Therapeutics; Three years later, divested portfolio for $203M to Piramal Critical Care (2x purchase price).

• Chief of Staff to the President and CEO

  • Mar 2012 - Jan 2014

  Led highly skilled team of big five consultants, investment bankers, and senior executives to develop company's equity value story and other key organizational strategies• Spearheaded establishment of governance structure to ensure operational excellence for critical company functions.• Advised and supported President, CEO, and Board of Directors regarding critical corporate initiatives, including decisions on strategy, structure, execution, and culture.• Acquired Cadence Pharmaceuticals for $1.4B, the company's first acquisition as a newly independent organization, by performing a vital role on the team responsible for sourcing, due diligence, and critical recommendations.• Launched novel products, in conjunction with the commercialization team, by guiding go-to-market strategy.

• Global Marketing Director - API's

  • Oct 2011 - Mar 2012

  Developed strategic plans, negotiated long-term contracts, and drove differentiation to support sustainable growth in highly competitive, mature markets across Europe, Japan, Australia, and the United States. Launched Naltrexone-based products to support numerous small pharmaceutical companies in their FDA filings and eventual commercial brand launch.

• Sales Director - North & South America

  • Oct 2009 - Oct 2011

  Led six seasoned executives with responsibility for $260M in sales to improve revenue by 3% and operating income by 5% for the division. Established an extensive global customer segmentation platform to streamline organizational efficiencies.

• US Field Sales Executive

  • May 2007 - Oct 2009

  Built and maintained key relationships in $60M territory. Implemented significant price increases to support sustainable growth. Exceeded sales goals in a saturated, mature market despite downward pricing pressure.

• Product Manager

  • Sep 2004 - May 2007

  Increased new product sales from $38M to $61M by leading key customer relationships and multi-functional teams (sales, manufacturing, quality, R&D, logistics) to expedite new product development timelines supporting NDA filings.

• Quality Lab Manager

  • Nov 2000 - Sep 2004

• Quality Analyst

  • Jan 2000 - Nov 2000